

Szebeni believes CARPA explains the severe anaphylactoid reactions some PEGylated drugs are occasionally known to cause, including **cancer blockbuster Doxil**. A team assembled by Bruce Sullenger, a surgeon at Duke University, **experienced similar issues** with an experimental anticoagulant containing PEGylated RNA. The team **had to halt a phase III trial in 2014** after about 0.6% of 1600 people who received the drug **had severe allergic responses and one participant died**. “That stopped the trial,” Sullenger says. The team found that every participant with an anaphylaxis had high levels of anti-PEG IgG.